<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435093</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0150</org_study_id>
    <secondary_id>2020-A01752-37</secondary_id>
    <nct_id>NCT04435093</nct_id>
  </id_info>
  <brief_title>Digitalization Playful Module of Motor Function Measure Assessment for Children With Neuromuscular Disorders, MFM-Play Pilot Study.</brief_title>
  <acronym>MFM-Play pilot</acronym>
  <official_title>Digitalization Playful Module of Motor Function Measure Assessment for Children With Neuromuscular Disorders, MFM-Play Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Motor Function Measure (MFM) is a functional rating scale consisting of 32 items&#xD;
      assessing motor functional abilities in a person with neuromuscular disease.&#xD;
&#xD;
      By exploring the potential of digital technologies applied to MFM, for each item completion&#xD;
      we want to create digital animations containing different playful and informative scenarios.&#xD;
      This digital evolution aims to standardize assessment on the therapist's side, but also to&#xD;
      improve acceptance of scale and patient participation.&#xD;
&#xD;
      Despite the modification of the MFM completion by digital animation, the study hypothesis is&#xD;
      that the metrological qualities of the scale are retained.&#xD;
&#xD;
      Through the MFM-Play pilot study, the objective is to test 5 items of the MFM-Play scale&#xD;
      before carrying out a validation study of the total MFM-Play.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Actual">March 4, 2021</completion_date>
  <primary_completion_date type="Actual">March 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MFM scores item 18 to 22</measure>
    <time_frame>Day 1</time_frame>
    <description>Level of agreement between the scores obtained during the classic mode and during the MFM-Play mode, completed by two different therapists.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Neuromuscular Diseases</condition>
  <arm_group>
    <arm_group_label>MFM completion</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MFM-Play</intervention_name>
    <description>Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.</description>
    <arm_group_label>MFM completion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will involve children with a neuromuscular disease, aged 6 to 11 years old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Girls and boys with a neuromuscular disease&#xD;
&#xD;
          -  Aged 6 to 11 years old&#xD;
&#xD;
          -  With parental assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients participating to a therapeutic trial&#xD;
&#xD;
          -  Patients without compartmental capacities to participate normally to the MFM.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Vincent-Genod</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuromuscular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromuscular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

